Peter is an infection immunologist by training with a PhD from ETH Zürich. With over 25 years of experience in research and development of vaccines and small molecules against bacterial and mycobacterial pathogens, he has worked with large pharma and small to mid-sized biotech in Switzerland and internationally. Peter has led and co-led diverse programs from hit-to-lead stage to preclinical and clinical development up to and including NDA preparations, and he was and is active as founder of startup companies. Since 2019, Peter is an independent contractor for companies and organizations active in research and development in the field of AMR. In 2023 he joined the management team of INCATE, with affiliation at the Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (Leibniz-HKI) in Jena, Germany.
The panel will address current strategies for early-stage funding chosen by the different panelists and give examples of successful company founding and funding. It will also address gaps and issues with the current funding landscape and within and between the supporting partners, and finally on novel business strategies chosen by the panelists to cope with those gaps. The addressed audience are start-ups, scientists and business developers in the AMR field and those planning to build a start-up, organizations supporting start-ups and everyone interested in early-stage development in the field of AMR.
Sponsored by LifeArc